Elanco Companion Animal Health has announced that its Duvaxyn IE and IE-T Plus vaccines have been licensed for active immunisation against OIE recommended clade 1 and clade 2 equine influenza strains, the first vaccines to be so licensed.
The company says the updated license is a result of a recent challenge study which demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to induce cross protection against clade 2 strain A/equi-2/Richmond/1/07 (H3N8) two weeks after two doses of the primary course1 were given. Cross-protection was further supported by another study2 measuring serum antibody response to the Richmond '07 strain 52 weeks after the three dose primary vaccination course.
The OIE (World Organisation for Animal Health) updated its equine influenza vaccine recommendations in 2010 to reflect the fact that all field strains characterised through 2008 and 2009 were of clade 1 or 2 of the Florida sub-lineage. The antigenic difference between viruses of these clades could potentially compromise the effectiveness of vaccines containing a representative of a single clade3.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health UK, said: "Whilst no vaccine has been updated to match the current OIE recommendations, the results of our challenge study and subsequent licence update provide reassurance that horses vaccinated with Duvaxyn will be protected against clinical signs of disease caused by currently circulating strains of equine influenza, including those the OIE has identified as being of concern.
"Further reassurance is also given with the confirmation in our study that Duvaxyn IE-T Plus elicits a cell mediated immune response, recognised to play an important role to aid in viral clearance and further enhances protection against strains circulating in the field." 4
The live virus challenge study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two doses of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Richmond/1/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Duvaxyn IE-T Plus is the only inactivated whole virus carbomer adjuvanted equine influenza vaccine in the UK. According to Elanco, experts in the field of human vaccination have expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins including the conserved nucleoprotein, which shows no antigenic drift, in the vaccine5.
References
Every UK-based veterinary surgeon that registers as a member of www.vetsurgeon.org by 1st November 2010 will be entered into a draw to win an Apple iPad 32GB Wi-Fi worth £500.
All existing veterinary surgeon members will also be entered into the draw automatically, so there's no need to re-register. Still, you might like to spread the word about the draw amongst colleagues.
Full terms and conditions are available by clicking here.
Anesketin solution for injection, containing Ketamine 100 mg/ml, is indicated for induction of anaesthesia. It can also be used as a sole agent for restraint and minor surgical procedures where muscle relaxation is not required in cats.
Anesketin was previously available in 10ml or 50ml bottles. Dechra says it has added the new 5ml vial in response to feedback from veterinary practices.
Dechra Brand Manager Craig Sankey said: "Anesketin is one of our most popular products in our range due to its versatility. It can be used in combination with appropriate sedatives and analgesics in cats, dogs and horses for induction of anaesthesia.
"5ml Anesketin will help practices comply with controlled drug legislation, saving time and effort in denaturing out of date stock and reducing wastage."
He added: "The introduction of the smaller bottle demonstrates our commitment to responding to the requirements of veterinary professionals and providing a range of high quality products that provide the most effective solution within day-to-day practice."
Support tools are available for customers to order online at www.dechra.co.uk, including an Anesketin controlled drug register.
The Royal Veterinary College and the Animal Health Trust are trying to recruit 3000 horse and pony owners to take part in 'CARE about laminitis', a web-based research project that aims to reduce the threat caused by laminitis.
The four-year study, which is being funded by World Horse Welfare, is being conducted by PhD student, Danica (Dee) Pollard, based at the AHT. The main aims of the study are to:
Currently the veterinary-reported frequency of laminitis in Britain, estimated between 2009 and 2011, shows that active episodes of veterinary-diagnosed laminitis occurred in nearly 1 in 200 horses/ponies registered with veterinary practices, and accounted for nearly 1 in 200 equine visits. Dee said: "However an overall lack of studies into the frequency of laminitis leaves little to compare these estimates with."
If you'd like to take part in the study, or invite clients to do so, visit: www.careaboutlaminitis.org.uk or email danica.pollard@aht.org.uk.
Merial is offering four free tubes of Eqvalan Duo to practices that buy 20 tubes in February and March. In addition, to further boost the targeted worming message, Merial will supply 20 free worm egg count vouchers worth £10 each.
Eqvalan Product Manager Claire Edmunds said: "Last year's campaign was so well received by both practices and clients that we have decided to run it again and are hoping for even better results!
"The personalised online planner, worm egg count offer and new eye-catching point of sale all help you to engage your clients in a targeted worming strategy.
For those practices with their own, in-house worm egg count testing facilities, Merial is also offering promotional support to help encourage increased uptake and client buy-in. The campaign forms part of Merial's promotion and education strategy for 2011, which includes extensive VN SQP CPD training opportunities.
To find out more contact your local Area Manager or call the Merial Customer Support Centre on 0845 601 4236
The company points to research which found that 89% of the veterinary profession wants to play a more active role in the sustainability agenda1.
For that reason, Boehringer says it put sustainability at the heart of Aservo EquiHaler, which uses no propellant gasses and the container for which is made from up to 50% recycled materials.
Now Boehringer has launched the first recycling programme for a prescription medicine in the UK to support the responsible disposal of the Aservo EquiHaler.
To join the programme, you need to visit: https://equihaler.uk/recycling, set up a TerraCycle account and register your practice. Boehringer says it only takes 10 minutes.
Once signed-up, a Boehringer Ingelheim Territory Manager will arrange for a collection box to be delivered, along with supporting practice display posters. When the box is full, there is a free pick-up service.
Practices that sign-up for the programme before 31st July 2021 will be entered into a prize draw, with the chance to win a year’s supply of ethically-sourced chocolate for their practice.
Reference:
I'm delighted to welcome Celia Marr from Rossdales and Edd Knowles from Bell Equine, who have kindly agreed to be our contributing experts. They'll drop in from time to time to add anything helpful they can to the forum discussions.
As elsewhere on VetSurgeon.org, reading content in the new groups or participating in discussions can count towards a VetSurgeon.org CPD certificate. Just press 'Claim CPD' at the top of the page, then collect the record and certificate from your profile.
All members of the site with an interest in equine medicine are now invited to press the join button on the left hand side of the group home page (when viewed on tablet or bigger). You may also wish to select the option to receive a daily or weekly digest of new content by email, which you can cancel at any time.
Equine is the third special interest group launched on VetSurgeon.org. The other two are Small Animal Medicine and Small Animal Dentistry.
Merial Animal Health has announced that the duration of immunity for the tetanus component of Proteqflu-Te has been extended to 2 years.
Merial's Veterinary Technical Manager Kevin Whelan said: "This is a welcome new addition to the label claims for this advanced vaccine, which is the only equine flu vaccine in the UK to contain a recently updated influenza virus strain. The updated strain, innovative canarypox vector technology and now the extended tetanus duration of immunity claim make the vaccine an excellent choice for vets in the UK"
Merial says Proteqflu-Te can now be used on an alternate year basis in combination with the company's other flu vaccine, Proteqflu, which does not contain tetanus toxoid. The one year duration of immunity for the influenza component remains unchanged.
Please contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
The National Equine Health Survey is an online snapshot survey designed to uncover common health issues in horses, directly from horse owners themselves. Results of the survey are used to build a picture of equine health and disease in the UK and define priorities for future research, training and education.
Over the past six years the survey, in partnership with the British Equine Veterinary Association, has developed to become one of the UK’s most important endemic disease monitoring initiative. The results are referenced in leading veterinary and equestrian publications and papers and are regarded as valuable benchmarks for our general knowledge of horse health.
Blue Cross Education Officer Gemma Taylor said: "These majestic police horses have taken part in our survey and we hope that they will encourage others to follow suit and be ambassadors for horse welfare.
"The more data we can collect from the National Equine Health Survey the more robust our results will be, helping us to steer equine awareness, education and research to keep our nation’s horses healthier."
Last year survey records were returned for almost 17,000 horses, ponies, donkeys and mules and the six most notable disease syndromes identified.
To take part in the National Equine Health Survey, visit: www.bluecross.org.uk/NEHS
To find out more about Blue Cross’s rescue and rehoming work with horses and ponies visit bluecross.org.uk
81% of equine worming strategies are not effective in fight against resistance, because owners are not conducting an adequate level of faecal egg counts (FEC), according to a survey carried out by Countrywide, the supplier of equestrian products.
The company surveyed nearly 1,000 horse owners in collaboration with Westgate Laboratories, Norbrook and BW Equine Vets and found that 47% have never conducted an FEC test.
When asked about their current approach to worming, 59% of respondents said they worm at set times of the year with only 31% conducting regular FEC tests.
Mark Hawkins, SQP at Countrywide, said: "With worms becoming resistant to some worming drugs, simply dosing all horses with routine wormers is not adequate. A targeted approach, which considers each horse as an individual, is needed."
Gillian Booth owner at Westgate Laboratories said: "The results show that the majority of horse owners are not updating their worming practice to match the increase in resistance and improvement in testing technology. Previous worming practices have led to the resistance problems we now have so it is vital that there is change."
The survey found that veterinary surgeons and in store advisors are vital to promote change - 65% of respondents actively seek advice from their vet and Suitably Qualified Person (SQP) for worming and general health care.
Mark added: “A huge 99% of people worm their horse at least once a year; despite this 38% of horse owners do not know an accurate weight of their horse. Considering inaccurate dosing plays a large role with the increase in resistance this figure is very concerning. If you do need to treat, accurate dosing is essential.”
The survey found that 86% of respondents had wormed for tapeworm, making it the most wormed for parasite. Despite this, only 6% of horse owners had conducted a saliva test for tapeworm, and only 8% had conducted the more established ELISA blood test through their vet to prove the need for this worming dose.
For a full breakdown of the survey results, visit: www.countrywidefarmers.co.uk/wormingsurvey.
Founded by Peter Rossdale in Newmarket in 1959, the practice now boasts a team of 50 veterinary surgeons and has established an international reputation for providing world class ambulatory, referral and laboratory services. The team is led by RCVS, European and American recognised veterinary specialists and operates from four sites in Newmarket, Exning, Hertfordshire and Lambourn.
Each year, Rossdales Equine Hospital in Exning hosts a large number of CPD courses which often include internationally recognised guest speakers who lecture alongside Rossdales’ specialist clinicians, with delegates attending from as far afield as Europe, Singapore, Dubai and Australia.
To celebrate the practice’s Diamond anniversary, Rossdales is hosting a special 'Diamond Series' of CPD events in 2019 in addition to its usual programme of educational courses.
Mike Shepherd, Managing Partner at Rossdales, said: "Since the practice was established by Peter Rossdale in 1959, it has always prided itself on clinical research and the willing distribution of this and other information to the veterinary profession. This ‘Diamond Anniversary’ series of CPD events is an initiative that we hope will benefit many of our veterinary colleagues. The first of these special events, the Diamond Series Veterinary Nursing Congress, was held at the beginning of June and was fully subscribed. We’re very pleased by the excellent feedback it generated."
Two further ‘Diamond Series’ events are scheduled, for veterinary surgeons and veterinary students respectively:
The Diamond Series Veterinary Surgeons Congress takes place on Friday,12th and Saturday, 13th July 2019 and is for all veterinary surgeons with an interest in equine or mixed practice. The programme covers a wide area of subjects, with talks provided by 12 veterinary surgeons from Rossdales Equine Hospital and Rossdales Laboratories. It also includes admission to The Moët & Chandon July Festival at Newmarket Racecourse on Saturday, 13th July.
The Diamond Series Undergraduate Congress will take place on Saturday, 10th and Sunday, 11th August 2019. This course is aimed at all current veterinary undergraduates who want to gain more knowledge and experience in the fields of equine veterinary medicine and surgery. There will be talks and presentations from 9 veterinary surgeons from Rossdales Equine Practice, Rossdales Equine Hospital and Rossdales Laboratories. There will also be a course dinner on the Saturday evening.
For more information, visit www.rossdales.com/news-events.
The Department for Environment, Food and Rural Affairs (Defra) and the Food Standards Agency (FSA) are reminding veterinary surgeons of their legal responsibilities under the Horse Passport Regulations 2009.
The move follows a small number of horses testing positively for the presence of phenylbutazone, which, if consumed, can be harmful to human health.
Defra and the FSA have asked for the assistance of the profession in ensuring that treatment with phenylbutazone is properly recorded in Horse Passports and have said that they are working together to understand the cause of the positive tests, and what longer term measures can be put in place to stop this happening.
In the interim, all horses slaughtered for human consumption will be sampled for the presence of phenylbutazone, with immediate effect.
The letter from Defra and the FSA can be downloaded from the RCVS website.
The full advice can be read in a Veterinary Medicines Directorate/Defra leaflet, which can be found online at http://www.vmd.defra.gov.uk/pdf/leaflet_horses.pdf.
Mark Bowen, Chair of the British Equine Veterinary Association's Health and Medicines Committee, said: "The number of horses entering the human food chain from the UK has doubled since 2009 and is no longer an insignificant minority of horses. All vets should be checking horse passports and only dispensing sensible quantities of this drug, and its prodrug suxibuzone."
Meanwhile, a form is available from the British Equine Veterinary Association website for veterinary surgeons to use if the horse passport is not available, but emergency treatment is required: http://www.beva.org.uk/_uploads/documents/emergency-treatment-form-no-passport-2011.pdf
CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.
Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.
The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.
Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.
Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.
Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.
CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/
Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial
Reference M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x
Six individuals have been announced as the winners of the second annual Ceva Animal Welfare Awards, honoured for their contributions to the prevention and reduction of animal welfare problems in the UK and abroad.
All winners were originally nominated by friends, colleagues or family. The judging panel consisted of panel chairman and veterinary surgeon Chris Laurence MBE, Ross Tiffin of the International Cat Care (formerly the Feline Advisory Bureau), Dennis Baker, OBE, Chief Executive at Wood Green, the Animal Charity and media vet, Joe Inglis. Marc Abraham also assisted in the Volunteer categories.
Dr. Pascal Raoul, Ceva's Head of Global Pharmaceuticals, said: "Ceva is delighted to host these Animal Welfare Awards as they help to highlight the incredible affection and care that people have for animals. With 6 billion people living in megacities in the future, companion animals will often be their major link to nature. The benefits that animals have on improving human health are well documented; in turn we all have a duty to protect them and this evening we have seen some of the best examples, from professionals, members of the public, young and old as to how that should be done."
Timothy Phillips, a Plymouth-based vet from the Elm Veterinary Group (above right), was awarded the Chris Laurence Vet of the Year Award for his 15 years of charitable work in the Greek Islands with Friends of the Strays of Greece. Tim performs surgeries and other treatments, helping to establish a re-homing system, with dogs fully vaccinated and declared healthy by the vets before being flown out of Greece.
Veterinary Nurse Scott Parry of Bridge Veterinary Surgery was awarded Welfare Nurse of the Year for his work with the RSPCA's Brent Knoll Animal Centre. Scott has spent hours of his own time raising funds and helping with the rehabilitation of a number of traumatised dogs. He also recently assisted in an RSPCA visit to a travellers' camp to vaccinate more than 50 dogs following an outbreak of Parvo Virus on the site.
Other award winners included Logan McKerron, aged 6, who was awarded Young Person of the Year for his fundraising for Hearing Dogs for Deaf People; Kim Taylor, co-founder of the charity Animal Care Egypt, was awarded the Charity Professional of the Year accolade for her work setting up a large animal hospital helping more than 26,000 animals every year; Faye Stacey of People4Ponies in Devon was awarded the UK Volunteer of the Year Award for the large part she has played in stopping ear cutting, notching and tagging of equines in the UK; Jen White has been named International Volunteer of the Year for her work with the Gambia Horse and Donkey Trust.
The company says it's not just older horses suffering from joint disease, 36% of horses developed the condition by the time they were eight years old.
In the survey, 69% of horses needed up to five visits to their veterinary surgeon for treatment, while 21% needed as many as ten visits. Horse owners spent an average of £2,104 treating their horse’s joint condition while 5% spent more than £7,500 on the problem.
In addition, 53% said they've missed up to ten competitions due to joint disease, with 17% missing more than 20 competitions.
The survey revealed that joint problems are an ongoing concern for many. 76% of owners said they worry about their horse developing osteoarthritis and 30% had retired a horse earlier than expected owing to joint disease. In addition, 84% admitted that they would not buy a horse if they knew it had joint problems.
In terms of joint care, 74% of respondents said they give their horse a joint supplement. 69% check their horse's legs daily and 90% implement post-competition leg care measures.
Cavalor’s Lieselot Hamerlinck said: "It is good to see that so many horse owners are using a joint supplement but it’s important that they understand what to look for when choosing which product to use. They should look for anti-inflammatory products, not just joint support and for clinical evidence on any product claims. It’s not just about giving a joint supplement every day, it’s more about giving the right product tailored to the horse’s individual needs.
"Also horse owners should be mindful that it is equally important, if not more so, to take proper care of their horse’s joints all year round, not just during competition."
For further information, visit www.cavalor.com.
Reference
Boehringer Ingelheim VetMedica has published its equine endocrine webinars online for veterinary professionals to view on demand at www.prascend.co.uk/webinars.
The webinars, which cover 'Diagnostic challenges in equine endocrine disease', presented by equine internal medicine specialist Andy Durham from the Liphook Equine Hospital, and 'A problem-based approach to equine laminitis', presented by equine internal medicine specialist Dr Catherine McGowan from the University of Liverpool, are each one hour long.
Participants will each receive CPD certificates for participation.
Licensed for the treatment of severe equine asthma, each Equipred tablet contains 50mg of prednisolone, a larger concentration tablet designed to make dosing easier.
Equipred tablets are available in boxes of 100 tablets and each tablet can be divided into halves and quarters for accurate dosing and precise tapering of the administered dose.
Rosie Naylor, Equine Technical Product Manager at Virbac said: "We are pleased to add Equipred to Virbac’s equine range. The novel 50mg tablet presentation will enable accurate dosing of horses that require orally administered steroid treatment".
For more information, contact your Virbac Territory Manager.
A team of top equine vets is aiming to raise £125,000 for the Society for the Protection of Animals Abroad (SPANA) by travelling 3000 miles through Europe by motorbike between 22nd August and 9th September.
Sponsored by Elanco Animal Health, the seven-strong team is planning to travel through Belgium, the Netherlands, Germany, Switzerland, France, Italy, Morocco and Spain and deliver lectures to eight European and African veterinary schools in just two weeks.
Led by Professor Derek Knottenbelt from the University of Liverpool, the team also includes Professor Josh Slater from Royal Veterinary College, Dr John Burford from the University of Nottingham, Dr Caroline Hahn from the University of Edinburgh, Dr Michael Hewetson from the University of Helsinki, Ms Joanne Suthers from the University of Liverpool and Dr Edmund Hainisch from the University of Vienna. They are being supported by Jeremy Hulme, chief executive of SPANA, Nic Van Gelder, fundraising and supporter care administrator at SPANA and Cerian Stephens.
All money raised will provide SPANA with diagnostic and surgical equipment for the charity's veterinary clinics for working animals in Mali and Mauritania and for the further development of the Bamako Disabled Riding Centre in Mali.
Mike Brown, Elanco's UK and Ireland country director said: "We are delighted to be sponsoring the Vets with Horsepower European Tour which will raise vital funds for working animals in some of the world's poorest countries. This is just one of the many worthwhile initiatives we are supporting in 2012 which focus on alleviating world hunger, spearheading agricultural leadership, enhancing the human-animal bond and caring for the environment."
For further information on the Vets with Horsepower European Tour visit www.spana.org/horsepower.
Sarah Gasper, BEVA’S Learning Manager said: "Many of us on the BEVA education team understand exactly what it’s like to return to practice whether after a career break, paternity/maternity or sickness leave. We also understand the specific challenges of moving from mixed into equine practice.
"We have created these courses to help make the transition back to work as smooth as possible. We’ve tried to incorporate everything we wish we had had access to when we returned to practice!"
Reinvigorate your approach to equine practice will be held on 12th March 2019 at Lythe Hill Hotel, Haslemere. The lecture and forum based course will explore the latest advances in internal medicine, orthopaedics, and sports medicine, and how to apply them to develop evidence-based clinical approaches to common and emergency scenarios in practice.
Getting (back) into equine practice will be held on 13th March 2019 at Liphook Equine Hospital, Hampshire. This entirely practical day of CPD will all be about improving the confidence of established equine vets and for vets returning to work following a career break. The course will focus on the practical procedures that an established equine ambulatory vet might be expected to perform on a regular basis. In a new approach to CPD we are trialling a system where delegates can shape part of this unique CPD day for themselves, with an online poll pre-course to select from a choice of practicals.
Both courses will have childcare facilities to help support parents wishing to attend CPD.
BEVA will also be running a course on the fundamentals of sedation, field anaesthesia and castration on 27th and 28th March 2019 at World Horse Welfare, Snetterton, Norfolk. This 'hands-on' course is designed for new or recent graduates or those in mixed practice with varied levels of equine work. It comprises evening lectures on the first day to free up more time for hands-on training on day two. It will cover sedation and field anaesthesia required for common field surgery such as castration, both in theory and in a practical session, with the equine welfare charity venue able to provide a high number of colts for castration work. Nerve blocks and regional anaesthesia for other common procedures will also be covered on cadavers.
For further information on BEVA’s new CPD courses visit www.beva.org.uk/cpd
A research project funded by equine charity The Horse Trust has succeeded in killing equine sarcoid cells in vitro by silencing a gene in the virus that causes sarcoids. The researchers are now hoping to obtain funding for clinical trials using the new technique, which could result in a more effective, non-toxic treatment for sarcoids.
Sarcoids are skin tumors caused by infection with the Bovine Papillomavirus (BPV). They are the most common type of tumour found in horses - the estimated prevalence in the UK is 6-7%. Although the disease is rarely life threatening, many horses with sarcoids are euthanased because the condition is untreatable or because the horse is unsellable. Currently there is no universally effective treatment for sarcoids and if treatment fails the sarcoids will often come back worse.
However, research that was given funding by The Horse Trust offers a potential ray of hope for owners of horses affected by sarcoids. The research was published in Virus Research journal earlier this year.
The research, which was led by Professor Lubna Nasir of the University of Glasgow, found that by inhibiting the activity of a particular viral protein within sarcoid cells, the amount of viral DNA in the cells reduced. This led to a reduction in the growth of the sarcoid cells and caused the cell to die by Programmed cell-death (PCD). The researchers believe that PCD occurs because the sarcoid cells become reliant on the virus.
Professor Nasir said: "This could potentially be a major breakthrough in the treatment of sarcoids. We are now seeking funding to use this technique in clinical trials on horses that have sarcoids."
The research team inhibited the activity of a viral protein called E2, which is needed by BPV to replicate. They used a novel approach termed 'gene silencing' to suppress the activity of the gene that codes the E2 protein. The research was carried out in vitro on fibroblast cells, which had been cultured from sarcoid tissue removed from animals during surgery.
As this research was carried out in vitro, the researchers will now need to see if they can replicate the results in vivo, by developing a way of targeting the sarcoid cells in horses.
"One of the challenges with gene silencing is administering it within clinical setting - as you need to get molecules into every cell. As sarcoids are on the surface of a horse, we think administration should be relatively easy - potentially by injecting or applying a cream to the sarcoid," said Professor Nasir. "If we are able to successfully develop this technique it would be a non-toxic and easy to administer treatment for horses affected by this distressing condition."
Nasir's research could also have an impact on the treatment of lesions in cattle, which are also caused by BPV. Around 50% of cattle in the UK are estimated to have lesions. It may also help with the treatment of Human Papillomavirus (HPV) infections in humans. HPV, which is similar to BPV, can lead to various cancers in humans including cervical and vaginal cancer.
Paul Jepson, Chief Executive and Veterinary Director of The Horse Trust said: "We are really excited that the research we have funded could lead to a major breakthrough in the treatment of sarcoids."
Bayer has introduced a new microchip scanner which is capable of reading all chips, including encrypted ones.
The company says the new Tracer Advance Isomax V scanner offers exceptional reading distances of more than twice those of other scanners on the market, making it a very versatile tool ideally suited for use in companion animal practices or for detecting microchips in larger animals such as horses.
The technology that gives this scanner its backward compatibility with non ISO standard chips means practices can now save money by only having to buy one scanner, whereas previously two were required to be able to read all types of chip.
Other features of the device include digital signal processing (DSP), which protects against radio interference from TVs and PCs, and connectivity via USB, RS232 or optional Bluetooth interface.
The Tracer Advance Isomax V scanner is available from Bayer and is priced at £499.95. It comes with a 30-month warranty. Contact your Bayer territory representative for further details.
Ridgeway Research Ltd has a surplus supply of short-dated Target IgG kits on special offer.
The kits are to test for passive transfer to foals via colostrum. Each kit contains 20 tests and normally costs £74. They have been reduced to £20 to clear. The use by date is end February 2010.
If you are interested, please email jo@ridgewayresearch.co.uk, or ring 01594 530809 for further information.
Renutend contains primed mesenchymal stem cells (MSCs) which Boehringer says are specifically targeted to reduce scar tissue formation so horses can return to the intended level of performance, with a reduced risk of re-injury1.
According to the company, a single dose decreases scar tissue formation with consistent and proven results 2.
RenuTend is administered by intralesional injection and complements Boehringer Ingelheim’s other equine stem cell product Arti-Cell Forte, which is authorised to treat mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.
RenuTend will be available in September this year.
In the meantime, Boehringer is encouraging veterinary surgeons to register their interest with their BIAH representative or call 01344746960 in order to get updates or product information as soon as it becomes available.
Having investigated alternative sources of isoflurane, and alternative products, the associations proposed ways that the VMD might mitigate the risks to animal welfare including consenting to the use of unlicensed (“special”) isoflurane formulations.
The VMD responded rapidly and positively. It is understood that one specials manufacturer is now intending to produce isoflurane to fill or partially fill the gap in supply. This should be available in three to four weeks.
David Rendle, a member of BEVA’s Health and Medicines Committee commented: "BEVA has a close relationship with the veterinary pharmaceutical industry and will always work swiftly and collaboratively to help develop practical solutions to supply problems for our members."
BSAVA President Philip Lhermette praised the VMD for such prompt action. He said: "The VMD listened to our concerns and acted immediately. By doing so they have addressed and helped to prevent any potential welfare risks associated with a lack of isoflurane."
Carl Bradbrook, AVA Junior Vice President, reminded clinicians to "seek advice when considering the use of unfamiliar anaesthetic protocols."
The associations say that the situation doesn’t give vets free rein to ignore the medicines legislation; the cascade must still be followed, and client informed consent obtained if an unregulated anaesthetic is used.
Extemporaneous products are the last tier of the cascade. Vets are expected to use either an authorised human medicine or an EU authorised veterinary medicine before an extemporaneous preparation. If, after diligent attempts to source a product higher up the cascade, the vet has not been successful they could consider using an extemporaneous preparation for the immediate need. However, should an authorised product or a human product become available vets are obliged to use it over an extemporaneous preparation.
BEVA, the BSAVA and the AVA have each produced general advice on the use of specials or anaesthesia options at https://www.bsava.com/News/ArticleID/2535/Isoflurane-supply, https://www.beva.org.uk/Resources-For-Vets-Practices/Medicines-Guidance/Veterinary-specials and https://ava.eu.com/